D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Microbiology D-index 64 Citations 14,002 447 World Ranking 876 National Ranking 394
Medicine D-index 73 Citations 19,901 619 World Ranking 13295 National Ranking 6978

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Antibiotics
  • Surgery

His main research concerns Antibacterial agent, Microbiology, Pharmacokinetics, Antibiotics and Pharmacodynamics. His research in Antibacterial agent intersects with topics in Anesthesia, Surgery, Meropenem, Tobramycin and Aminoglycoside. His Microbiology research is multidisciplinary, relying on both Pseudomonas aeruginosa, Klebsiella pneumoniae, In vivo and Staphylococcus aureus.

Pharmacokinetics is a subfield of Pharmacology that David P. Nicolau tackles. His study in Antibiotics is interdisciplinary in nature, drawing from both Area under the curve and Intensive care medicine. His Pharmacodynamics study combines topics from a wide range of disciplines, such as Telithromycin and Tazobactam.

His most cited work include:

  • Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. (498 citations)
  • Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. (216 citations)
  • Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection (200 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Microbiology, Antibiotics, Pharmacokinetics, Pharmacodynamics and Antibacterial agent. David P. Nicolau interconnects Pseudomonas aeruginosa, Klebsiella pneumoniae, In vivo and Staphylococcus aureus in the investigation of issues within Microbiology. In his research, Antibiotic resistance is intimately related to Intensive care medicine, which falls under the overarching field of Antibiotics.

The various areas that he examines in his Pharmacokinetics study include Gastroenterology and Anesthesia. His Pharmacodynamics research is multidisciplinary, incorporating elements of Regimen, Minimum inhibitory concentration, Cephalosporin and Dosing. His Antibacterial agent research is multidisciplinary, incorporating perspectives in Aminoglycoside and Streptococcus pneumoniae.

He most often published in these fields:

  • Microbiology (40.50%)
  • Antibiotics (26.87%)
  • Pharmacokinetics (23.38%)

What were the highlights of his more recent work (between 2018-2021)?

  • Microbiology (40.50%)
  • Pseudomonas aeruginosa (16.50%)
  • Meropenem (17.25%)

In recent papers he was focusing on the following fields of study:

David P. Nicolau mainly focuses on Microbiology, Pseudomonas aeruginosa, Meropenem, Pharmacokinetics and Pharmacodynamics. The Microbiology study combines topics in areas such as In vitro and In vivo. David P. Nicolau has included themes like Amikacin, Enterobacterales and Pneumonia in his Pseudomonas aeruginosa study.

The Pharmacokinetics portion of his research involves studies in Pharmacology and Internal medicine. David P. Nicolau works mostly in the field of Pharmacology, limiting it down to topics relating to Antimicrobial and, in certain cases, Antibiotic resistance, as a part of the same area of interest. In his study, Vancomycin and Intensive care medicine is strongly linked to Antibiotics, which falls under the umbrella field of Pharmacodynamics.

Between 2018 and 2021, his most popular works were:

  • Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint (23 citations)
  • Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial (20 citations)
  • Evaluation of the EDTA-Modified Carbapenem Inactivation Method for Detecting Metallo-β-Lactamase-Producing Pseudomonas aeruginosa (19 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Antibiotics
  • Bacteria

His scientific interests lie mostly in Microbiology, Pseudomonas aeruginosa, Meropenem, Pharmacodynamics and Antibiotics. David P. Nicolau combines subjects such as Klebsiella pneumoniae, In vitro and In vivo with his study of Microbiology. His Meropenem study combines topics in areas such as Ceftazidime, Aztreonam, Potency and Fosfomycin.

His Pharmacodynamics study results in a more complete grasp of Pharmacokinetics. His Pharmacokinetics study incorporates themes from Gastroenterology and Renal function. His studies deal with areas such as Vancomycin, Dosing and Intensive care medicine as well as Antibiotics.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

D P Nicolau;C D Freeman;P P Belliveau;C H Nightingale.
Antimicrobial Agents and Chemotherapy (1995)

761 Citations

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.

Collin D. Freeman;David P. Nicolau;Paul P. Belliveau;Charles H. Nightingale.
Journal of Antimicrobial Chemotherapy (1997)

326 Citations

Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection

Melinda K. Lacy;Wen Lu;Xiaowei Xu;Pamela R. Tessier.
Antimicrobial Agents and Chemotherapy (1999)

306 Citations

Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections

Chonghua Li;Xiaoli Du;Joseph L. Kuti;David P. Nicolau.
Antimicrobial Agents and Chemotherapy (2007)

273 Citations

The pharmacodynamics of aminoglycosides

Melinda K. Lacy;David P. Nicolau;Charles H. Nightingale;Richard Quintiliani.
Clinical Infectious Diseases (1998)

268 Citations

Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.

Joseph L. Kuti;Prachi K. Dandekar;Charles H. Nightingale;David P. Nicolau.
The Journal of Clinical Pharmacology (2003)

244 Citations

Adherence to Highly Active Antiretroviral Therapy Predicts Virologic Outcome at an Inner-City Human Immunodeficiency Virus Clinic

JoCarol McNabb;Jack W. Ross;Kenneth Abriola;Christina Turley.
Clinical Infectious Diseases (2001)

222 Citations

Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae

Catharine C. Bulik;David P. Nicolau.
Antimicrobial Agents and Chemotherapy (2011)

215 Citations

Relationship between Fluoroquinolone Use and Changes in Susceptibility to Fluoroquinolones of Selected Pathogens in 10 United States Teaching Hospitals, 1991–2000

Marcus J. Zervos;Marcus J. Zervos;Ellie Hershberger;Ellie Hershberger;David P. Nicolau;David J. Ritchie;David J. Ritchie.
Clinical Infectious Diseases (2003)

212 Citations

Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.

David P Nicolau;JoCarol McNabb;Melinda K Lacy;Richard Quintiliani.
International Journal of Antimicrobial Agents (2001)

203 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing David P. Nicolau

Jason A. Roberts

Jason A. Roberts

Royal Brisbane and Women's Hospital

Publications: 225

Jeffrey Lipman

Jeffrey Lipman

Royal Brisbane and Women's Hospital

Publications: 224

Matteo Bassetti

Matteo Bassetti

University of Genoa

Publications: 121

Michael J. Rybak

Michael J. Rybak

Eugene Applebaum College of Pharmacy and Health Sciences

Publications: 104

George G. Zhanel

George G. Zhanel

University of Manitoba

Publications: 57

David L. Paterson

David L. Paterson

University of Queensland

Publications: 57

Matthew E. Falagas

Matthew E. Falagas

Alfa Institute of Biomedical Sciences

Publications: 54

Johan W. Mouton

Johan W. Mouton

Erasmus University Rotterdam

Publications: 51

Ronald N. Jones

Ronald N. Jones

JMI Laboratories

Publications: 48

Robert A. Bonomo

Robert A. Bonomo

United States Department of Veterans Affairs

Publications: 43

Hartmut Derendorf

Hartmut Derendorf

University of Florida

Publications: 38

Vincent H. Tam

Vincent H. Tam

University of Houston

Publications: 37

Fabio Silvio Taccone

Fabio Silvio Taccone

Université Libre de Bruxelles

Publications: 35

James A. Karlowsky

James A. Karlowsky

University of Manitoba

Publications: 35

Helio S. Sader

Helio S. Sader

JMI Laboratories

Publications: 34

Daryl J. Hoban

Daryl J. Hoban

University of Manitoba

Publications: 33

Something went wrong. Please try again later.